Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:06:12.148Z.
Consensus retrieved: unavailable. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:06:12.148Z.
Quote observation: 2026-10-06T15:03:21.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 003104a745df447911be4c5a9e680832c7b19445192e606e8359fbce1df4db86
FORWARD PE RATIO
N/A
Clearmind Medicine Inc.
Market Cap
$1.09M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Clearmind Medicine Inc. (CMND) | $1.09M | N/A |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.11M | N/A |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.02M | N/A |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.18M | N/A |
| IM Cannabis Corp. (IMCC)vs › | $1.19M | N/A |
| Bone Biologics Corporation (BBLG)vs › | $870069.00 | N/A |
| GlucoTrack, Inc. (GCTK)vs › | $861994.00 | N/A |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $838118.00 | N/A |
| Decoy Therapeutics Inc. (DCOY)vs › | $829870.00 | N/A |
| Genprex, Inc. (GNPX)vs › | $1.36M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus fiscal-year EPS
Consensus estimates for this stock are reported in USD, while the share price trades in USD — so per-fiscal-year implied multiples can't be computed honestly here. The analyst estimates table shows the consensus figures with their correct currency label.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
